FDA to expand drug research on pregnant women, filling decades-old safety gap
H.R. 8651 — Advancing Safe Medications for Moms and Babies Act of 2026 · Filed by Kathy Castor (D-FL) · 2 cosponsors · Introduced May 4, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the FDA to update its regulations to make it easier for pregnant and lactating women to participate in clinical drug trials, establishes a $5 million/year public education campaign to inform patients and doctors about these trials, and funds the National Institutes of Health to prioritize research on drugs used by pregnant and lactating women. The goal is to fill a gap in medical knowledge about drug safety during pregnancy and breastfeeding.
Why we flagged it
The bill's operative mechanism is regulatory harmonization, public education funding, and research prioritization—all aimed at expanding the evidence base for drug safety in pregnancy and lactation. No private carve-outs, no liability shields, no narrow beneficiaries.
What the text implies
- Regulatory harmonization may create new compliance burdens for pharmaceutical companies conducting trials, potentially increasing trial costs and timelines—though the bill does not shield companies from these costs.
- The education campaign and research prioritization process may increase demand for enrollment in pregnancy-related clinical trials, which could accelerate drug development timelines for maternal health indications.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical companies conducting maternal health research; clinical research organizations specializing in obstetrics and pediatrics; medical device manufacturers with pregnancy-related products